We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Greiner Bio-One

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
14 Jul 2020 - 14 Jul 2020
Virtual Venue
15 Jul 2020 - 19 Jul 2020
Virtual Venue

Flexible Stent Treats Iliofemoral Venous Occlusive Disease

By HospiMedica International staff writers
Posted on 25 Mar 2019
Print article
Image: The Venovo stent is specifically designed for arteries (Photo courtesy of BD).
Image: The Venovo stent is specifically designed for arteries (Photo courtesy of BD).
A novel stent treats iliofemoral venous occlusive disease (IVOD), the obstruction or narrowing of blood flow specific to the iliac and femoral veins, located near the groin.

The BD (Franklin Lakes, NJ, USA) Venovo venous stent is specifically designed to reopen blocked iliac and femoral veins in order to maintain adequate blood flow in symptomatic IVOD post-thrombotic and non-thrombotic lesions. The flexible nitinol stent maintains a balance of radial strength, compression resistance, and flexibility specifically designed to meet the demands of veins, as opposed to arteries. For example, the ends are flared to enhance vein-wall apposition, and broad stent sizing allows clinicians to treat large diameter veins (10-20 mm) and long lesion lengths (from 40 mm to 160 mm). Six radiopaque tantalum markers aid in positioning.

A prospective, multicenter, single-arm trial involving 170 patients showed a weighted primary patency rate of 88.3%, with a 96.9% patency rate in non-thrombotic lesions and an 81.3% patency rate in post-thrombotic lesions at 12 months, exceeding the performance goal of 74%. In addition, patients treated with the Venovo reported a significant reduction in pain symptoms and improvement in quality of life at 12 months from baseline. The Venovo venous stent was also deployed successfully to the target lesion and showed adequate coverage in all cases, and there were no fractures seen at 12 months.

“The Venovo venous stent represents a significant advance for interventionalists treating iliofemoral venous occlusive disease, an under recognized condition,” said Steve Williamson, worldwide president of peripheral intervention at BD. "We designed the Venovo venous stent in collaboration with clinicians to enable them to treat both post-thrombotic and non-thrombotic lesions. Clinicians will now have access to the broadest range of stent sizes in the United States for these difficult-to-treat lesions.”

“The unique attributes of the Venovo stent make it particularly well-suited to treat iliofemoral occlusive disease,” said Michael Dake, MD, of the University of Arizona, the principal investigator for the Venovo U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) trial. “Most importantly, it is purpose-built for application in veins, and engineered to address the special challenges of venous lesions that are very different than those posed by arterial narrowing.”

IVOD occurs when there is impaired blood flow in the iliofemoral vein caused by acute or chronic deep-vein thrombosi (DVT), post-thrombotic syndrome, iliofemoral vein compression (including May-Thurner Syndrome), or a combination of these diseases. Symptoms include swelling of the legs, pain when standing, skin discoloration and ulcers.

Print article



view channel

Omnia Health Live Unites Global Healthcare Community Through New Virtual Experience

Omnia Health Live, a virtual healthcare event, has brought the global healthcare community together on a scale never seen before through a new experience delivered entirely online. The virtual healthcare... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.